Inhaled Antibiotics in Cystic Fibrosis (CF) and Non-CF Bronchiectasis

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Seminars in Respiratory and Critical Care Medicine

• Publication date

  2015-03-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.1055/s-0035-1547346PMID 25826593
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines.

  2015cited by this paper
• Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.

  2015cited by this paper
• A novel microbiota stratification system predicts future exacerbations in bronchiectasis.

  2014cited by this paper
• Emerging cystic fibrosis pathogens and the microbiome.

  2014cited by this paper
• European Cystic Fibrosis Society Standards of Care: Best Practice guidelines.

  2014cited by this paper
• Emerging drugs for cystic fibrosis

  2014cited by this paper
• Three clinically distinct chronic pediatric airway infections share a common core microbiota.

  2014cited by this paper
• Inhaled antibiotics: dry or wet?

  2014cited by this paper
• Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial.

  2014cited by this paper
• The Cost Effectiveness of Dry Powder Antibiotics for the Treatment of Pseudomonas aeruginosa in Patients with Cystic Fibrosis

  2014cited by this paper
• Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials.

  2014cited by this paper
• Emerging inhalation aerosol devices and strategies: where are we headed?

  2014cited by this paper
• Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores

  2014cited by this paper
• Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection.

  2014cited by this paper
• Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis.

  2014cited by this paper
• Analysis of Changes in Diversity and Abundance of the Microbial Community in a Cystic Fibrosis Patient over a Multiyear Period

  2014cited by this paper
• Dry powder inhalers in cystic fibrosis: same old drugs but different benefits?

  2014cited by this paper
• Antimicrobial treatment of non-cystic fibrosis bronchiectasis

  2014cited by this paper
• Pyrosequencing reveals transient cystic fibrosis lung microbiome changes with intravenous antibiotics

  2014cited by this paper
• Predominant pathogen competition and core microbiota divergence in chronic airway infection

  2014cited by this paper
• Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review

  2014cited by this paper
• [Inhaled treatments in cystic fibrosis: what's new in 2013?].

  2014cited by this paper
• A preliminary quality of life questionnaire-bronchiectasis: a patient-reported outcome measure for bronchiectasis.

  2014cited by this paper
• Aztreonam for inhalation solution, challenges to drug approval and integration into CF care.

  2013cited by this paper
• Mechanisms of airway remodeling.

  2013cited by this paper
• Nebuliser systems for drug delivery in cystic fibrosis.

  2013cited by this paper
• Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation.

  2013cited by this paper
• Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis.

  2013cited by this paper
• Nebuliser systems for drug delivery in cystic fibrosis.

  2013cited by this paper
• Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial

  2013cited by this paper
• Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection

  2013cited by this paper
• Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition

  2013cited by this paper
• Does extensive genotyping and nasal potential difference testing clarify the diagnosis of cystic fibrosis among patients with single-organ manifestations of cystic fibrosis?

  2013cited by this paper
• Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.

  2013cited by this paper
• Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health.

  2013cited by this paper
• Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial.

  2013cited by this paper
• Isoniazid‐gelatin conjugate microparticles containing rifampicin for the treatment of tuberculosis

  2013cited by this paper
• Treatment of lung infection in patients with cystic fibrosis: current and future strategies.

  2012cited by this paper
• Role of cystic fibrosis transmembrane conductance regulator in patients with chronic sinopulmonary disease.

  2012cited by this paper
• Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection.

  2012cited by this paper
• Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study

  2012cited by this paper
• The Adult Cystic Fibrosis Airway Microbiota Is Stable over Time and Infection Type, and Highly Resilient to Antibiotic Treatment of Exacerbations

  2012cited by this paper
• Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study

  2012cited by this paper
• Safety, ef fi cacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fi brosis: a randomised study

  2012cited by this paper
• Lower airway microbiology and cellularity in children with newly diagnosed non‐CF bronchiectasis

  2012cited by this paper
• Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand

  2011cited by this paper
• Inhaled antibiotics for long-term therapy in cystic fibrosis.

  2011cited by this paper
• Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa.

  2011cited by this paper
• Pharmacokinetics and Safety of MP-376 (Levofloxacin Inhalation Solution) in Cystic Fibrosis Subjects

  2011cited by this paper
• Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa.

  2011cited by this paper
• Anaerobic bacteria in cystic fibrosis: pathogens or harmless commensals?

  2011cited by this paper
• New guidelines for the management of adult lower respiratory tract infections

  2011cited by this paper
• Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial

  2011cited by this paper
• Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.

  2011cited by this paper
• Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis

  2011cited by this paper
• Infection and remodelling: a 21st century model of bronchiectasis?

  2011cited by this paper
• A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis.

  2011cited by this paper
• The airway microbiome in cystic fibrosis and implications for treatment

  2011cited by this paper
• Antibiotic resistance of bacterial biofilms.

  2010cited by this paper
• British Thoracic Society guideline for non-CF bronchiectasis

  2010cited by this paper
• Pseudomonas aeruginosa biofilms in cystic fibrosis.

  2010cited by this paper
• An 18‐month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis

  2010cited by this paper
• British Thoracic Society guideline for non-CFbronchiectasis

  2010cited by this paper
• Respiratory bacterial pathogens in the nasopharynx and lower airways of Australian indigenous children with bronchiectasis.

  2010cited by this paper
• Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis.

  2010cited by this paper
• Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.

  2009cited by this paper
• Nanomagnetosols: magnetism opens up new perspectives for targeted aerosol delivery to the lung.

  2008cited by this paper
• Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis.

  2008cited by this paper
• Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.

  2008cited by this paper
• Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections.

  2008cited by this paper
• A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection

  2008cited by this paper
• Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms

  2008cited by this paper
• Endobronchial biopsy in childhood.

  2008cited by this paper
• Endobronchial biopsy in childhood.

  2007cited by this paper
• Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis.

  2007cited by this paper
• Effect of pH on the antimicrobial susceptibility of planktonic and biofilm-grown clinical Pseudomonas aeruginosa isolates

  2007cited by this paper
• Targeted delivery of magnetic aerosol droplets to the lung

  2007cited by this paper
• Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

  2007cited by this paper
• Characterisation of the onset and presenting clinical features of adult bronchiectasis.

  2006cited by this paper
• Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.

  2006cited by this paper
• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.

  2006cited by this paper
• Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis

  2006cited by this paper
• Switch from planktonic to sessile life: a major event in pneumococcal pathogenesis

  2006cited by this paper
• Haemophilus influenzae forms biofilms on airway epithelia: implications in cystic fibrosis.

  2006cited by this paper
• Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.

  2005cited by this paper
• Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms

  2005cited by this paper
• Inhaled Tobramycin in Non—Cystic Fibrosis Patients with Bronchiectasis and Chronic Bronchial Infection with Pseudomonas Aeruginosa

  2005cited by this paper
• Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease

  2004cited by this paper
• Severe bronchiectasis

  2003cited by this paper
• Validation of the Hong Kong Chinese version of the St. George Respiratory Questionnaire in patients with bronchiectasis.

  2002cited by this paper
• Bronchiectasis in Indigenous children in remote Australian communities

  2002cited by this paper
• Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients.

  2002cited by this paper
• Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin.

  2002cited by this paper
• Clinical, laboratory findings and microbiologic characterization of bronchiectasis in Thai patients

  2002cited by this paper
• Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis

  2002cited by this paper
• A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis

  2002cited by this paper
• Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis.

  2002influential reference
• Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors

  2002cited by this paper
• Treatment With tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa.

  2001cited by this paper
• Altered intracellular pH regulation in neutrophils from patients with cystic fibrosis.

  2000cited by this paper

• Insights on the Pathogenesis of Mycobacterium abscessus Infection in Patients with Cystic Fibrosis

  2025cites this paper
• Phenotype Analysis of Chronic Bronchial Infection Patients on Inhaled Antibiotic Therapy: A Multicentre Retrospective Cohort Study in Spain (INBREATHING Study).

  2025cites this paper
• Comparative microbiome analysis in cystic fibrosis and non-cystic fibrosis bronchiectasis.

  2024cites this paper
• Bronchiectasis in Childhood.

  2022cites this paper
• Pseudomonas aeruginosa Pneumonia: Evolution of Antimicrobial Resistance and Implications for Therapy.

  2022cites this paper
• Maintenance of Pulmonary Therapies

  2020cites this paper
• Observations of, and Insights into, Cystic Fibrosis Mucus Heterogeneity in the Pre-Modulator Era: Sputum Characteristics, DNA and Glycoprotein Content, and Solubilization Time

  2020cites this paper
• Chronic Lung Disease in Primary Antibody Deficiency: Diagnosis and Management.

  2020cites this paper
• A role of thiamphenicol glycinate acetylcysteinate for therapy of respiratory diseases (a review)

  2020cites this paper
• Тиамфеникола глицинат ацетилцистеинат – место в терапии респираторных заболеваний (обзор литературы)

  2020cites this paper
• Treatment of Pulmonary Manifestations of Primary Immunodeficiency Diseases

  2019cites this paper
• Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1).

  2019cites this paper
• Comorbidities and their impact

  2018cites this paper
• A Prospective Trial of Nebulized Amikacin in the Treatment of Bronchiectasis Exacerbation

  2018cites this paper
• The efficacy of inhaled antibiotics in non-cystic fibrosis bronchiectasis

  2018cites this paper
• Bronchiectasis: Treatment decisions for pulmonary exacerbations and their prevention

  2018cites this paper
• 291 – Pharmacokinetic-Pharmacodynamic Basis of Optimal Antibiotic Therapy

  2018cites this paper
• CHANG Bronchiectasis : Treatment decisions for pulmonary exacerbations and their prevention

  2018cites this paper
• INVITED REVIEW SERIES: PAEDIATRIC AND ADULT BRONCHIECTASIS

  2018cites this paper
• The treatment of the pulmonary and extrapulmonary manifestations of cystic fibrosis.

  2017cites this paper
• Emergence of Antimicrobial Resistance among Pseudomonas aeruginosa: Implications for Therapy

  2017cites this paper
• Inhaled Antibiotic Therapy for the Treatment of Upper Respiratory Tract Infections

  2017cites this paper
• An update on the pharmacotherapeutic management of lower respiratory tract infections

  2017cites this paper
• The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis

  2017influential citation
• Pediatric bronchiectasis: No longer an orphan disease

  2016cites this paper
• Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration

  2016cites this paper
• Non-CF-Bronchiektasen: Aktuelle therapeutische Entwicklungen

  2016cites this paper
• Bronchiectasis: Current Concepts in Pathogenesis, Immunology, and Microbiology.

  2016cites this paper
• Safety of Drugs during Pregnancy and Breastfeeding in Cystic Fibrosis Patients

  2016cites this paper
• Transmission of Bacteria during Cystic Fibrosis Educational Programs

  2016cites this paper
• Sinonasal pathology in Cystic Fibrosis

  2016cites this paper
• Phenotyping in bronchiectasis: Are we moving toward a personalized medicine?

  2016cites this paper
• Molecular Epidemiology of Mutations in Antimicrobial Resistance Loci of Pseudomonas aeruginosa Isolates from Airways of Cystic Fibrosis Patients

  2016cites this paper
• Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis

  2015cites this paper
• [Inhaled medication and inhalation devices for lung disease].

  2015cites this paper
• Drug interactions and treatment burden as survival improves

  2015cites this paper
• Inhaled antibiotics: the new era of personalized medicine?

  2015cites this paper